Etranacogene dezaparvovec (AMT-061 phase 2b): Normal/near normal FIX activity and bleed cessation in hemophilia B

Annette Von Drygalski, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan Lattimore, Frank W.G. Leebeek, Wolfgang Miesbach, Michael Recht, Alison Long, Robert Gut, Eileen K. Sawyer, Steven W. Pipe

Research output: Contribution to journalArticle

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)3241-3247
Number of pages7
JournalBlood Advances
Volume3
Issue number21
DOIs
StatePublished - Nov 12 2019

ASJC Scopus subject areas

  • Hematology

Cite this

Drygalski, A. V., Giermasz, A., Castaman, G., Key, N. S., Lattimore, S., Leebeek, F. W. G., Miesbach, W., Recht, M., Long, A., Gut, R., Sawyer, E. K., & Pipe, S. W. (2019). Etranacogene dezaparvovec (AMT-061 phase 2b): Normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Advances, 3(21), 3241-3247. https://doi.org/10.1182/bloodadvances.2019000811